May 4, 2023 5:01 PM | 2 min read

Analysts have provided the following ratings for Myriad Genetics (NASDAQ:MYGN) within the last quarter:

These 4 analysts have an average price target of $23.25 versus the current price of Myriad Genetics at $21.09, implying upside.

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Below is a summary of how these 4 analysts rated Myriad Genetics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

The Best Report Benzinga Has Ever Produced

Massive returns are within possible within this market! For a limited time, get access to the Benzinga Insider Report, usually $47/month, for just $0.99! Discover extremely undervalued stock picks before they skyrocket! Time is running out! Act fast and secure your future wealth at this unbelievable discount!

Claim your $0.99 offer NOW!

This average price target has increased by 12.48% over the past month.

Stay up to date on Myriad Genetics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Originally posted here:
Where Myriad Genetics Stands With Analysts - Myriad Genetics (NASDAQ:MYGN) - Benzinga